WO2005095355A1 - N,n’-カルボニルジイミダゾールの製造方法 - Google Patents
N,n’-カルボニルジイミダゾールの製造方法 Download PDFInfo
- Publication number
- WO2005095355A1 WO2005095355A1 PCT/JP2005/005891 JP2005005891W WO2005095355A1 WO 2005095355 A1 WO2005095355 A1 WO 2005095355A1 JP 2005005891 W JP2005005891 W JP 2005005891W WO 2005095355 A1 WO2005095355 A1 WO 2005095355A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- imidazole
- producing
- inert solvent
- carbodiimidazole
- general formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Definitions
- the present invention relates to a method for producing ⁇ , N′-carbonyldiimidazole. More specifically, according to a method for producing ⁇ , N′-carbonyldiimidazole by reacting imidazole with phosgene or a polymer thereof in an inert solvent, imidazole hydrochloride by-produced and a basic conjugate are produced.
- the present invention relates to a process for circulating and using imidazole produced by a neutralization reaction with a gas or liquid as a raw material for producing ⁇ , N'-carbonyldiimidazole. Background art
- ⁇ , N'-carbodiimidazole (hereinafter abbreviated as CDI) is used for pharmaceutical synthesis such as condensation reaction between molecules, intramolecular condensation reaction such as synthesis of ⁇ ⁇ ⁇ ⁇ -carboxylic acid anhydride, and formation of activated ester. It is a valuable compound used in fields such as biochemical synthesis, agricultural chemical synthesis, and peptide synthesis.
- the most common method of synthesizing CDI is to react imidazole with phosgene in an inert solvent designed by H. A. Staab. In this method, as shown in the following chemical formula, half of the imidazole is used as a scavenger for hydrogen chloride formed during the reaction, and is separated and removed from CDI after the reaction is completed.
- Patent Document 1 International Publication No. 98Z31672 pamphlet
- Patent Document 2 International Publication No. 00Z02863 pamphlet
- Patent Document 3 International Publication No. 00Z14072 pamphlet
- Patent Document 4 International Publication No.OOZ06551 pamphlet
- the present inventors have conducted intensive studies to solve this problem.
- imidazole hydrochloride by-produced during the reaction is dissolved or dispersed in an organic solvent, the imidazole hydrochloride is neutralized with a gas or liquid of a basic compound, and the neutralized product is removed.
- R 2 ⁇ R 3 R 3 each independently represents a hydrogen atom, a methyl group or an ethyl group.
- the present invention also relates to each of the following. That is, the above-mentioned method for producing N, N, 1-carbodiimidazole wherein the basic compound represented by the general formula (1) is gaseous ammonia or liquid ammonia;
- the inert solvent is one or a mixture of two or more selected from the group consisting of chain ethers, cyclic ethers, and chain ester esters.
- Imidazole produced by the neutralization reaction of by-product imidazole hydrochloride with the basic compound represented by the general formula (1) is taken out as a solid by crystallization or removal of the solvent, and is used for the production of N, N'-carbonyldiimidazole.
- the imidazole produced by the neutralization reaction between the by-product imidazole hydrochloride and the basic compound represented by the general formula (1) is converted into an inert solvent solution or a dispersion slurry of the inert solvent.
- the neutralization reaction with the basic compound represented by the formula (1) is carried out in an inert solvent, the hydrochloride of the basic compound is removed by filtration, and the imidazole formed is directly treated with the inert compound.
- N, N'-carbo which is circulated and used as a raw material for the production of N, N'-carboldiimidazole without adding a water removing step as a solvent solution or a slurry of the inert solvent.
- the imidazole formed by the neutralization reaction between the by-product imidazole hydrochloride and the basic compound represented by the general formula (1) and imidazole newly supplied are mixed in an arbitrary ratio, and N, N, and carboxy are mixed.
- imidazole hydrochloride is neutralized by an organic base and neutralized without generation of water as occurs when neutralizing with an inorganic base.
- the basic conjugate represented by the general formula (1) is inexpensive and easy to handle.
- the basic compound represented by the general formula (1) has a low boiling point, and even if the basic compound represented by the general formula (1) remains in the system after completion of the neutralization reaction, boiling or Since it can be easily removed by publishing with an inert gas, there is no adverse effect due to the residual basic conjugate during CDI synthesis by recycle use of imidazole.
- the hydrochloride of the basic compound represented by the general formula (1) generated during the neutralization reaction is removed by filtration.
- the imidazole that has been neutralized to a free state can be recycled in the form of a solution or as a solid after distilling off the solvent and used as a raw material for CDI production without adding a water removal step. it can.
- the imidazole formed is used as a solution of an inert solvent or a dispersion slurry of the inert solvent.
- the neutralization reaction between the by-product imidazole hydrochloride and the basic conjugate represented by the general formula (1) is performed in an inert solvent, and the hydrochloric acid of the basic conjugate is treated with hydrochloric acid.
- the salt may be removed by filtration, and the resulting imidazole may be circulated and used as it is as a solution of the inert solvent or a dispersion slurry of the inert solvent.
- Phosgene, diphosgene or triphosgene is reacted with imidazole to produce N, N'-force liponyldiimidazole.
- phosgene or by-produced hydrogen chloride does not react. As long as it is an active solvent, deviation can also be used. Also, even when the solvent has some reactivity, such a solvent can be used because the reaction between imidazole and phosgene and the reaction between imidazole and hydrogen chloride are preferred.
- imidazole hydrochloride by-produced during the production of CDI is neutralized by adding a gas or liquid of a basic compound which is inexpensive and easy to handle!
- the imidazole can be recovered in a free state without producing water. After that, it became possible to circulate imidazole easily and inexpensively as a raw material for CDI production without adding processes such as extraction and azeotropic dehydration. Further, according to the production method of the present invention, CDI with less coloring can be obtained as compared with the conventional production method.
- imidazole hydrochloride used in the present invention it is preferable to use imidazole hydrochloride by-produced during the production of CDI in consideration of the purpose of the present invention, but imidazole hydrochloride synthesized separately or other imidazole hydrochloride may be used. Imidazole hydrochloride by-produced during the production of the compound may be used.
- the basic conjugate used in the present invention is particularly limited as long as it is represented by the general formula (1). Not determined.
- RR 2 and R 3 are each independently a hydrogen atom, a methyl group or an ethyl group.
- ammonia, methylamine, dimethylamine, trimethylamine, ethylamine, getylamine, triethylamine, methylethylamine, ethyldimethylamine, and among the above-mentioned powers ammonia is preferably used.
- the inert solvent is not particularly limited as long as it does not inhibit the reaction between imidazole and phosgenes and the neutralization reaction of imidazole hydrochloride.
- Specific examples of the inert solvent that can be used in the present invention include cyclic ethers such as tetrahydrofuran and dioxane, chain ethers such as diisopropyl ether and dibutyl ether, and halogenated hydrocarbons such as dichloromethane, chloroform and trichloroethane.
- Aromatic hydrocarbons such as toluene, xylene, and chlorobenzene, chain esters such as ethyl acetate and butyl acetate, ketones such as acetone and methyl isobutyl ketone, -tolyls such as acetonitrile, and hexane And aliphatic hydrocarbons such as heptane.
- chain ethers, cyclic ethers and chain esters and particularly preferred is tetrahydrofuran.
- These organic solvents may be used alone or in combination of two or more.
- the neutralization reaction of the basic compound with imidazole hydrochloride by gas or liquid is carried out by dissolving or dispersing the imidazole hydrochloride in an inert solvent and introducing the basic compound. It is preferred to do so.
- imidazole hydrochloride is added to an inert solvent in which a basic compound is dissolved, or an imidazole hydrochloride dissolved or dispersed in an inert solvent is poured. .
- the basic conjugate used for neutralizing imidazole hydrochloride is used in an amount of 1 to 10 times the molar amount of imidazole hydrochloride. Preference is given to using 1 to 5 moles.
- the inert solvent used for neutralizing imidazole hydrochloride is used in an amount of 1 to 20 times the weight of imidazole hydrochloride. It is preferable to use 3 to 5 times the weight.
- the neutralization reaction of the basic conjugate of imidazole hydrochloride with a gas or liquid is usually performed at 0 to 100 ° C. It is preferably carried out at 20 to 50 ° C.
- the reaction time is usually 0.5 to 20 hours. Preferably, it is performed in 2 to 8 hours.
- the reaction is preferably performed under an inert gas atmosphere such as nitrogen or argon under anhydrous conditions, but the atmosphere conditions are not particularly limited.
- the reaction solution after completion of the neutralization reaction is preferably filtered under an inert gas atmosphere and under anhydrous conditions in which a neutralized product is filtered at an arbitrary temperature, but the atmosphere conditions are not particularly limited.
- the recovered filtrate containing imidazole is used as it is or after concentration, as a raw material for CDI production. Further, imidazole is taken out as a solid by an operation such as crystallization and used as a raw material for CDI production.
- the neutralized and recovered imidazole is dissolved or dispersed in an inert solvent and then subjected to a CDI synthesis reaction by introducing a specified amount of phosgene, diphosgene or triphosgene. At this time, a new imidazole may be added to the neutralized and recovered imidazole, and the unit yield of CDI may be increased to perform the reaction.
- the filtrate containing CDI was concentrated and crystallized from toluene, and the CDI was filtered off under a nitrogen atmosphere.
- the filtered CDI was dried under reduced pressure at 40 ° C. to obtain 58.0 g (0.358 mol) of CDI white crystals. (Yield 90%) m.p. 111.2-118.6. C.
- CDI produced by the production method of the present invention can be used for pharmaceutical synthesis, agricultural chemical synthesis, peptide synthesis, etc., such as intermolecular condensation reaction, intramolecular condensation reaction such as synthesis of N-carboxylic anhydride, and formation of activated ester. It is a valuable compound used in fields such as synthesis, and is particularly suitable for applications requiring no coloration.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006511676A JP4846568B2 (ja) | 2004-03-30 | 2005-03-29 | N,n’−カルボニルジイミダゾールの製造方法 |
US11/547,524 US7964626B2 (en) | 2004-03-30 | 2005-03-29 | Process for producing N,N′-carbonyldiimidazole |
CA2562131A CA2562131C (en) | 2004-03-30 | 2005-03-29 | Process for producing n,n'-carbonyldiimidazole |
KR1020067020399A KR101126954B1 (ko) | 2004-03-30 | 2005-03-29 | N,n'-카르보닐디이미다졸의 제조 방법 |
EP05727492.0A EP1731510B1 (en) | 2004-03-30 | 2005-03-29 | Process for producing n,n'-carbonyldiimidazole |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-099257 | 2004-03-30 | ||
JP2004099257 | 2004-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005095355A1 true WO2005095355A1 (ja) | 2005-10-13 |
Family
ID=35063691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/005891 WO2005095355A1 (ja) | 2004-03-30 | 2005-03-29 | N,n’-カルボニルジイミダゾールの製造方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7964626B2 (ja) |
EP (1) | EP1731510B1 (ja) |
JP (1) | JP4846568B2 (ja) |
KR (1) | KR101126954B1 (ja) |
CA (1) | CA2562131C (ja) |
HU (1) | HUE027644T2 (ja) |
WO (1) | WO2005095355A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013047738A1 (ja) * | 2011-09-30 | 2013-04-04 | Meiji Seikaファルマ株式会社 | グルホシネートp遊離酸の製造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111892569A (zh) * | 2019-05-05 | 2020-11-06 | 石家庄圣泰化工有限公司 | 4,4’-联-1,3-二氧戊环-2,2’-二酮的合成方法 |
CN112851506B (zh) * | 2020-12-31 | 2023-06-23 | 湖北英纳氏生物科技有限公司 | 一种3,5-二甲氧基-4-烷基苯甲醇的工业化制备方法 |
KR102559870B1 (ko) * | 2021-04-27 | 2023-07-26 | 주식회사 켐얼라이언스 | 카르밤산염 화합물의 제조방법 |
CN113307774B (zh) * | 2021-05-17 | 2023-03-24 | 山东汇海医药化工有限公司 | 一种从咪唑盐酸盐废水中回收咪唑的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08502994A (ja) * | 1992-11-13 | 1996-04-02 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | 2,4−オキサゾリジンジオン類の製造方法 |
WO2000002863A1 (de) * | 1998-07-08 | 2000-01-20 | Basf Aktiengesellschaft | Verfahren zur herstellung von carbonyldiimidazolen |
JP2002503240A (ja) * | 1997-06-12 | 2002-01-29 | ビーエーエスエフ アクチェンゲゼルシャフト | カルボニルジイミダゾール、そのエステル誘導体およびその製造方法 |
JP2002521474A (ja) * | 1998-07-28 | 2002-07-16 | バイエル アクチェンゲゼルシャフト | N,n’−カルボニルジアゾールの製造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19826936A1 (de) | 1998-06-17 | 1999-12-23 | Basf Ag | Verfahren zur Herstellung von Carbonyldiimidazol |
US6455702B1 (en) * | 2001-05-16 | 2002-09-24 | Aims Fine Chemicals, Inc. | Process for the production of N,N-carbonyl diimidazole |
-
2005
- 2005-03-29 EP EP05727492.0A patent/EP1731510B1/en not_active Not-in-force
- 2005-03-29 WO PCT/JP2005/005891 patent/WO2005095355A1/ja active Application Filing
- 2005-03-29 KR KR1020067020399A patent/KR101126954B1/ko active IP Right Grant
- 2005-03-29 US US11/547,524 patent/US7964626B2/en active Active
- 2005-03-29 JP JP2006511676A patent/JP4846568B2/ja active Active
- 2005-03-29 HU HUE05727492A patent/HUE027644T2/en unknown
- 2005-03-29 CA CA2562131A patent/CA2562131C/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08502994A (ja) * | 1992-11-13 | 1996-04-02 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | 2,4−オキサゾリジンジオン類の製造方法 |
JP2002503240A (ja) * | 1997-06-12 | 2002-01-29 | ビーエーエスエフ アクチェンゲゼルシャフト | カルボニルジイミダゾール、そのエステル誘導体およびその製造方法 |
WO2000002863A1 (de) * | 1998-07-08 | 2000-01-20 | Basf Aktiengesellschaft | Verfahren zur herstellung von carbonyldiimidazolen |
JP2002521474A (ja) * | 1998-07-28 | 2002-07-16 | バイエル アクチェンゲゼルシャフト | N,n’−カルボニルジアゾールの製造方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013047738A1 (ja) * | 2011-09-30 | 2013-04-04 | Meiji Seikaファルマ株式会社 | グルホシネートp遊離酸の製造方法 |
US9255115B2 (en) | 2011-09-30 | 2016-02-09 | Meiji Seika Pharma Co. Ltd. | Method for producing glufosinate P free acid |
Also Published As
Publication number | Publication date |
---|---|
EP1731510A1 (en) | 2006-12-13 |
JP4846568B2 (ja) | 2011-12-28 |
HUE027644T2 (en) | 2016-10-28 |
CA2562131A1 (en) | 2005-10-13 |
US7964626B2 (en) | 2011-06-21 |
US20090088575A1 (en) | 2009-04-02 |
KR20070002034A (ko) | 2007-01-04 |
EP1731510A4 (en) | 2010-08-04 |
EP1731510B1 (en) | 2015-07-29 |
JPWO2005095355A1 (ja) | 2008-02-21 |
CA2562131C (en) | 2013-11-26 |
KR101126954B1 (ko) | 2012-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5461712B2 (ja) | N−(ブロモアセチル)−3,3−ジニトロアゼチジンの合成及び単離法並びにそれを含む組成物 | |
JPS6033436B2 (ja) | ハロシリルカルバメ−トおよびその製造方法 | |
WO2005095355A1 (ja) | N,n’-カルボニルジイミダゾールの製造方法 | |
JP3680203B2 (ja) | 4−アセチルアミノベンゼンスルホニルアジドの製造方法 | |
JP3732061B2 (ja) | 2−アルキル−4−イソチアゾリン−3−オン類の製造方法 | |
CN107530327A (zh) | 制备2‑噻吩甲酰氯的方法 | |
US4060536A (en) | Method of preparing N,N'-bis-trimethylsilylurea | |
JPH02200661A (ja) | アルカンスルホンアミド類の製法 | |
CN113583021B (zh) | 一种螺哌啶利福霉素的合成方法 | |
WO1999054281A1 (fr) | Procede de production de dimethylacetamide | |
KR102589305B1 (ko) | 시타글립틴 인산염의 개선된 제조방법 | |
JP4078975B2 (ja) | 3,4−ジヒドロキシベンゾニトリルの製法 | |
JP4913589B2 (ja) | 1,2−ベンズイソキサゾール−3−メタンスルホンアミドのワンポット製造法 | |
JPS59501B2 (ja) | グアニジノカゴウブツノシンセイゾウホウホウ | |
CN107108490A (zh) | 含氮五氟硫基苯化合物的制造方法 | |
JP2724901B2 (ja) | メチルフェニルトリシロキサン類の製造方法 | |
JP2000290258A (ja) | 新規なイミダゾール誘導体及びその製造方法 | |
KR100310936B1 (ko) | N-(4-메틸벤젠술포닐)-n'-(3-아자바이시클로[3,3,0]옥탄)우레아의 제조방법 | |
JP2004323392A (ja) | ビテトラゾールアミン化合物の製造方法 | |
JPS5946255A (ja) | 2−アルコキシメチレン−3,3−ジアルコキシプロパンニトリル類の製法 | |
JPH09202751A (ja) | ジt−ブチルジカーボネートの製造方法 | |
JP2002534495A (ja) | アゾイミノエーテル及びアゾカルボン酸エステルの製造方法並びに新規のアゾカルボン酸混合エステル | |
KR20230099857A (ko) | 우라피딜 제조 중간체의 제조방법 | |
JPS6130580A (ja) | チアゾリジン−2−オン類の製造法 | |
WO2018159028A1 (ja) | N-ベンジル-2-ブロモ-3-メトキシプロピオン酸アミド及びその中間体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511676 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727492 Country of ref document: EP Ref document number: 1020067020399 Country of ref document: KR Ref document number: 2562131 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727492 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067020399 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11547524 Country of ref document: US |